Yiqian Liu

Dr. Yiqian Liu


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

18 November 2021 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
HXHuanhuan Xu
Huanhuan Xu
QLQi Liang
Qi Liang
XXXian Xu
Xian Xu
STShanyue Tan
Shanyue Tan
SWSumeng Wang
Sumeng Wang
LLLingxiang Liu
Lingxiang Liu
Background: HER2 is a member of the ERBB family of receptor tyrosine kinases, and HER2 mutations occur in 1–4% of non-small cell lung cancer (NSCLC) as an oncogenic driver mutation. We found a rare mutation of HER2 p.Asp769Tyr in NSCLC. Case presentation: We presented a case of a 68-year-old nonsmoking male patient with brain metastasis from lung adenocarcinoma harboring a rare mutation of HER2 p.Asp769Tyr. After multiple lines of treatment, he obtained a durable response (10 months) to afatinib and anlotinib. Conclusion: We reported for the first time that afatinib and anlotinib have successfully treated lung adenocarcinoma with HER2 p.Asp769Tyr mutation. This finding can provide an insight into the optimal treatment of lung adenocarcinoma patients with novel mutations. Additionally, we summarized the efficacy of targeted therapy for HER2 mutant lung cancer in this article.

24 December 2025 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
WYWenhui Yang
Wenhui Yang
YZYanxiang Zhang
Yanxiang Zhang
MGMinghui Ge
Minghui Ge
LLLuyao Liu
Luyao Liu
YSYongqian Shu
Yongqian Shu
YLYiqian Liu
Yiqian Liu
Gastrointestinal (GI) cancers impose a significant global health burden and germline gene alterations play a significant role in the malignant transformati